Glutathione S-transferases as emerging therapeutic targets

BOOTH J, 1961, Biochem. I, 79, 516, 10.1042/bj0790516

BABBITT PC, 2000, Proc. Natl. Acad. Sci. USA, 97, 10298, 10.1073/pnas.97.19.10298

BOARD PG, 2000, j Biol. Chem., 275, 24798, 10.1074/jbc.M001706200

MORGENSTERN R, 1985, Primary structure. I Biol. Chem., 260, 13976

DIRR H, 1994, Implications for protein architecture, substrate recognition and catalytic function. Eur. j Biochem., 220, 645

ARMSTRONG RN, 1997, Chem. Res. Toxicol., 10, 2, 10.1021/tx960072x

ATKINS WM, 1993, Spectroscopic determination of the pKa of Tyr-9 in rat alpha 1-1 GST. I Biol. Chem., 268, 19188

MEYER DJ, 1995, Biochem. I, 306, 565, 10.1042/bj3060565

DULHUNTY A, 2001, J Bid. Chem., 276, 3319, 10.1074/jbc.M007874200

JURONEN E GT, UUSKULA M, POOGA M, MIKELSAAR AV, 1996, Biochem. Mol. Biol. Int., 39, 21

HAYES JD, 2000, Pharmacology, 61, 154, 10.1159/000028396

REBBECK TR, 1997, Cancer Epidemiol Biomarkers Prey, 6, 733

LAN Q HEX, 2000, Cancer Epidemiol Biomarkers Prey, 9, 605

SCHLADE-BARTUSIAK K, 2000, Mutat. Res., 465, 69, 10.1016/S1383-5718(99)00213-2

SALAMA SA, 1999, Pharmacogenetics, 9, 735, 10.1097/00008571-199912000-00008

LANDI S, 2000, Mutat. Res., 463, 247, 10.1016/S1383-5742(00)00050-8

SARHANIS P, Br I Cancer, 1996, 1757

LALLAS TA, 2000, Cancer Epidemiol Biomarkers Prey, 9, 587

SPURDLE AB, 2001, Carcinogenesis, 22, 67, 10.1093/carcin/22.1.67

ZHONG S, Carcinogenesis, 1993, 1821

HOULSTON RS, 1999, Cancer Epidennol. Biomarkers Prey., 8, 675

ALT-OSMAN F, 1997, Evidence for differential catalytic activity of the encoded proteins. J. Biol. Chem., 272, 10004

HARRIES LW, 1997, Carcinogenesis, 18, 641, 10.1093/carcin/18.4.641

SWEENEY C McCLURE, 2000, Cancer Res, 60, 5621

HIDA T, 1994, Potential predictive value in chemotherapeutic response. Cancer, 73, 1377

HOWIE AF, 1990, Carcinogenesis, 11, 295, 10.1093/carcin/11.2.295

CHEN YK, 1995, J. Oral. Pathol. Med., 24, 316, 10.1111/j.1600-0714.1995.tb01192.x

ZHANG L, 1994, J. Oral Pathol. Med., 23, 75, 10.1111/j.1600-0714.1994.tb00260.x

CHEN YK, 1997, Int. j Ora] Maxillolac. &mg., 26, 205, 10.1016/S0901-5027(97)80820-X

WANG X, 1997, Clin. Cancer Res., 3, 111

BENTZ BG, Laryngoscope, 2000, 1642

HIRAZONO K, 1995, J. Obstet. CynaecoL, 21, 305, 10.1111/j.1447-0756.1995.tb01015.x

GREEN JA, 1993, Br Cancer, 68, 235, 10.1038/bjc.1993.321

GERMAIN I, 1996, Int. J. CynecoL Pathol., 15, 54, 10.1097/00004347-199601000-00009

KODATE C, 1986, fpn. Cancer Res., 77, 226

10.1002/path.1711660105

SMITH MT, 1989, Cancer Res, 49, 2621

CIACCIO PJ, 1991, Biochem. Pharmacy]., 42, 1504, 10.1016/0006-2952(91)90468-K

BATIST G, 1986, J. Biol. Chem., 261, 15544, 10.1016/S0021-9258(18)66748-1

TEW KD, 1994, Cancer Res., 54, 4313

WANG YY, 1989, Cancer Res., 49, 6185

FAIRCHILD CR, 1990, Md. PharmacoL, 37, 801

DOROSHOW JH, 1995, Cancer Res, 55, 4073

NAKAGAWA K, 1990, j Biol. Chem., 265, 4296, 10.1016/S0021-9258(19)39562-6

O'BRIEN ML, 1999, PharmacoL Exp. Ther., 291, 1348

CIACCIO PJ, 1990, Cancer Commun, 2, 279, 10.3727/095535490820874263

BLACK SM, 1990, Biochem., 268, 309, 10.1042/bj2680309

PUCHALSKI RB, 1990, Proc. Natl. Acad. Sd. USA, 87, 2443, 10.1073/pnas.87.7.2443

GREENBAUM M, 1994, Cancer Res, 54, 4442

NISHIMURA T, 1996, Gin Cancer Res, 2, 1859

SHIGA H, 1999, Clin. Cancer Res., 5, 4097

BOKU N, 1998, CBI]. Cancer Res., 4, 1469

UOZAKI H, 1997, Relationship with poor prognosis. Cancer, 79, 2336

KONISHI I, 1998, Cynecol. Oncol., 70, 365, 10.1006/gyno.1998.5077

VENERONI S, 1997, Oral Oncol., 33, 408, 10.1016/S0964-1955(97)00036-5

ALPERT LC, 1997, Clin. Cancer Res., 3, 661

TEW KD, 1988, Cancer Res., 48, 3622

HALL A, 1989, Cancer Res, 49, 6265

10.1016/0304-3835(91)90198-Q

CLAPPER ML, 1990, J. Cell. Pharmacol., 1, 71

OAKLEY AJ, 1997, FEBS Lett, 419, 32, 10.1016/S0014-5793(97)01424-5

MULDER TI PETERS WH, WOBBES T, WITTEMAN BJ, JANSEN JB, 1997, Cancer, 80, 873, 10.1002/(SICI)1097-0142(19970901)80:5<873::AID-CNCR7>3.0.CO;2-M

O'DWYER PJ, 1991, Phase I study of thiotepa in combination with the glutathione transferase inhibitor ethacrynic acid. Cancer Res., 51, 6059

10.1111/j.1365-2141.1993.tb03187.x

KHIL MS, 1996, Int. J. Radiat. Oncol. Biol. Phys., 34, 375, 10.1016/0360-3016(95)02040-3

SINGH SV, 1998, Carcinogenesis, 19, 1357, 10.1093/carcin/19.8.1357

ADANG AE, 1990, Investigation of the cysteinyl, glycyl and gamma-glutamyl domains. Biochem., 269, 47

ASKELOF P, 1975, Biochem. J., 147, 513, 10.1042/bj1470513

FLATGAARD JE, 1993, Cancer Chemother. Pharmacol., 33, 63, 10.1007/BF00686025

10.1021/jm00027a024

ANDERSON ME, 1985, Arch. Biochem. Biophys., 239, 538, 10.1016/0003-9861(85)90723-4

MORGAN AS, 1996, Cancer Chemother. Pharmacol., 37, 363, 10.1007/s002800050398

RUSCOE JE, 2001, J. Pharmacol. Exp. Ther., 298, 339

WANG T, 2001, J. Biol. Chem., 276, 20999, 10.1074/jbc.M101355200

YIN Z, 2000, Cancer Res, 60, 4053

OUWERKERK-MAHADEVAN S, 1995, Biochem., 308, 283, 10.1042/bj3080283

KUGA T, 1997, Hum. Gene Ther., 8, 1901, 10.1089/hum.1997.8.16-1901

MORGAN AS, 1998, Cancer Res, 58, 2568

O'BRIEN M, 2000, j Pharmacol. Exp. Ther., 294, 480

ROSARIO LA O&amp;apos, 2000, Pharmacol, 58, 167

DAVIS W JR., 2001, j Pharmacol. Exp. Ther., 296, 1

SAITOH M, 1998, EMBO, 17, 2596, 10.1093/emboj/17.9.2596

WANG AL, 1985, Cancer Treat Rep., 69, 677

PETRINI M Di, 1995, Br j Haematol, 90, 393, 10.1111/j.1365-2141.1995.tb05164.x

KLYS HS, 1992, Br j Cancer, 66, 589, 10.1038/bjc.1992.319

KANBAGLI O, 2000, fpri Cancer Res., 91, 1258